Tolero Pharmaceuticals has signed a licence agreement with MannKind to develop and commercialise Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of haematological malignancies and inflammatory diseases.

Under the agreement, Tolero will pay MannKind upfront and milestone payments linked to the development, approval and commercialisation of products, with a potential total value of approximately $130m.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

MannKind, which will receive tiered royalties on sales of products and a percentage of the sublicensing revenue, has an option to reacquire the rights to the programme under pre-specified terms until 60 days after the completion of the first phase 1 study.

MannKind will assume responsibility for developing and commercialising products, if the company exercises the option, and Tolero would then be entitled to receive the milestone payments, royalties and sublicensing revenues specified in the agreement.

Dallin Anderson, Tolero chairman and president, said BTK currently represents one of the most exciting therapeutic targets in oncology and the company believes that the collaborative approach to targeting BTK may uncover some new utilities not yet fully realised.

See Also:

Tolero founder David Bearss said that BTK has already been shown to be a validated clinical target in multiple disease settings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We believe that MannKind has developed a series of novel compounds with unique mechanisms of action that may lead to important treatments for cancer and autoimmune diseases, such as rheumatoid arthritis," Bearss added.

Tolero is a biopharmaceutical company focused on the discovery and development of therapeutics to treat and cure cancer and other life-threatening diseases and MannKind focuses on the discovery, development and commercialisation of therapeutic products for patients with diseases such as diabetes and cancer.